Kelly K Hunt

List of Publications by Year
in descending order

181	8,651	50244	53190
papers	citations	46 h-index	85 g-index

190	190	190	9025
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	American College of Surgeons Commission on Cancer Standard for Curative-intent Pulmonary Resection. Annals of Thoracic Surgery, 2022, 113, 5-8.	0.7	18
2	Breast Implant-associated Anaplastic Large Cell Lymphoma. Annals of Surgery, 2022, 275, e245-e249.	2.1	15
3	Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. Annals of Surgical Oncology, 2022, 29, 1489-1492.	0.7	15
4	Palbociclib plus endocrine therapy significantly enhances overall survival of <scp>HR</scp>+/<scp>HER2</scp>â˜ metastatic breast cancer patients compared to endocrine therapy alone in the secondâ€line setting: A large institutional study. International Journal of Cancer, 2022, 150, 2025-2037.	2.3	16
5	<scp>Realâ€world</scp> use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center. International Journal of Cancer, 2022, 150, 2012-2024.	2.3	8
6	Abstract P2-05-02: Low molecular weight cyclin E facilitate replication stress tolerance in breast cancer development. Cancer Research, 2022, 82, P2-05-02-P2-05-02.	0.4	0
7	Sarculator is a Good Model to Predict Survival in Resected Extremity and Trunk Sarcomas in US Patients. Annals of Surgical Oncology, 2022, 29, 4376-4385.	0.7	12
8	Technical Standards for Cancer Surgery: Commission on Cancer Standards 5.3â€“5.8. Annals of Surgical Oncology, 2022, , 1.	0.7	7
9	ASO Visual Abstract: Sarculator is a Good Model to Predict Survival in Resected Extremity and Trunk Sarcomas in US Patients. Annals of Surgical Oncology, 2022, , 1.	0.7	0
10	ASO Author Reflections: Technical Standards for Cancer Surgery: From â€œHow I Do Itâ€• to â€œHow We Do Itâ€• Annals of Surgical Oncology, 2022, 29, 6559-6560.	0.7	2
11	Clinical Outcomes Using Magnetic Seeds as a Non-wire, Non-radioactive Alternative for Localization ofÂNon-palpable Breast Lesions. Annals of Surgical Oncology, 2022, 29, 3822-3828.	0.7	8
12	Sentinel Lymph Node Biopsy and Formal Lymphadenectomy for Soft Tissue Sarcoma: A Single Center Experience of 86 Consecutive Cases. Annals of Surgical Oncology, 2022, 29, 7092-7100.	0.7	8
13	National Cancer Database trends in surgical resection of the breast primary for stage IV breast cancer. Surgical Oncology, 2022, , 101778.	0.8	2
14	Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031). Clinical Cancer Research, 2022, 28, 3287-3295.	3.2	6
15	Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer. Annals of Surgery, 2021, 274, e150-e159.	2.1	5
16	Evaluating the Impact of Surveillance Follow-Up Intervals in Patients Following Resection of Primary Well-Differentiated Liposarcoma of the Retroperitoneum. Annals of Surgical Oncology, 2021, 28, 570-575.	0.7	4
17	MYC and NOTCH1â€positive postradiation cutaneous angiosarcoma of the breast. Breast Journal, 2021, 27, 264-267.	0.4	3
18	Breast Sarcomas, Phyllodes Tumors, and Desmoid Tumors: Epidemiology, Diagnosis, Staging, and Histology-Specific Management Considerations. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 390-404.	1.8	12

#	Article	IF	Citations
19	Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020. JAMA Network Open, 2021, 4, e210945.	2.8	66
20	Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer. JAMA Oncology, 2021, 7, 609.	3.4	15
21	Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration. Cancers, 2021, 13, 1656.	1.7	16
22	LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers. Oncogenesis, 2021, 10, 40.	2.1	2
23	Breast implant-associated anaplastic large cell lymphoma: clinical follow-up and analysis of sequential pathologic specimens of untreated patients shows persistent or progressive disease. Modern Pathology, 2021, 34, 2148-2153.	2.9	11
24	Impact of the early COVIDâ€19 pandemic on Breast Surgical Oncology fellow education. Journal of Surgical Oncology, 2021, 124, 989-994.	0.8	7
25	Clinical Course of Breast Cancer Patients with Local-Regional Progression During Neoadjuvant Systemic Therapy. Annals of Surgical Oncology, 2021, 28, 5477-5485.	0.7	3
26	Epsteinâ€“Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship. Modern Pathology, 2021, 34, 2154-2167.	2.9	25
27	Inflammatory Breast Cancer at the Extremes of Age. Annals of Surgical Oncology, 2021, 28, 5626-5634.	0.7	5
28	Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state. Acta Neuropathologica, 2021, 142, 565-590.	3.9	12
29	Prospective Registry Trial Assessing the Use of Magnetic Seeds to Locate Clipped Nodes After Neoadjuvant Chemotherapy for Breast Cancer Patients. Annals of Surgical Oncology, 2021, 28, 4277-4283.	0.7	21
30	ASO Visual Abstract: Clinical Course of Breast Cancer Patients with Local Regional Progression During Neoadjuvant Systemic Therapy. Annals of Surgical Oncology, 2021, , 1.	0.7	0
31	A proposal for pathologic processing of breast implant capsules in patients with suspected breast implant anaplastic large cell lymphoma. Modern Pathology, 2020, 33, 367-379.	2.9	29
32	Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors. Annals of Surgical Oncology, 2020, 27, 359-366.	0.7	5
33	Comparative Analysis of Proposed Strategies for Incorporating Biologic Factors into Breast Cancer Staging. Annals of Surgical Oncology, 2020, 27, 2229-2237.	0.7	6
34	Management and outcomes of ruptured, perforated or fistulized tumors of mesenchymal origin. Journal of Surgical Oncology, 2020, 121, 474-479.	0.8	1
35	Opioid Use after Breast-Conserving Surgery: Prospective Evaluation of Risk Factors for High Opioid Use. Annals of Surgical Oncology, 2020, 27, 730-735.	0.7	12
36	Postoperative pancreatic fistula after distal pancreatectomy for non-pancreas retroperitoneal tumor resection. American Journal of Surgery, 2020, 220, 140-146.	0.9	9

#	Article	IF	Citations
37	The Landmark Series: Axillary Management in Breast Cancer. Annals of Surgical Oncology, 2020, 27, 724-729.	0.7	36
38	Reply to A. Thomsen et al. Journal of Clinical Oncology, 2020, 38, 3577-3577.	0.8	1
39	Clinical trialsâ€"Designing, implementing, and collaborating. Journal of Surgical Oncology, 2020, 122, 25-28.	0.8	2
40	Cytoplasmic Cyclin E Is an Independent Marker of Aggressive Tumor Biology and Breast Cancer-Specific Mortality in Women over 70 Years of Age. Cancers, 2020, 12, 712.	1.7	3
41	Quantitative 3-Dimensional Photographic Assessment of Breast Cosmesis After Whole Breast Irradiation for Early Stage Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. Advances in Radiation Oncology, 2020, 5, 824-833.	0.6	7
42	Specific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancer. British Journal of Cancer, 2020, 122, 812-822.	2.9	11
43	Effect of Surgeon Factors on Long-Term Patient-Reported Outcomes After Breast-Conserving Therapy in Older Breast Cancer Survivors. Annals of Surgical Oncology, 2020, 27, 1013-1022.	0.7	7
44	Clinical Trials for the Surgical Oncologist: Opportunities and Hurdles. Annals of Surgical Oncology, 2020, 27, 2269-2275.	0.7	4
45	Effectiveness and Safety of Magseed Localization for Excision of Breast Lesions. Annals of Surgery Open, 2020, 1, e008.	0.7	18
46	Multidisciplinary Management of Locoregional Recurrent Breast Cancer. Journal of Clinical Oncology, 2020, 38, 2321-2328.	0.8	25
47	SentimagIC: A Non-inferiority Trial Comparing Superparamagnetic Iron Oxide Versus Technetium-99m and Blue Dye in the Detection of Axillary Sentinel Nodes in Patients with Early-Stage Breast Cancer. Annals of Surgical Oncology, 2019, 26, 3510-3516.	0.7	47
48	Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection. JAMA Surgery, 2019, 154, 800.	2.2	58
49	Differences in Human Leukocyte Antigen Expression Between Breast Implantâ€"Associated Anaplastic Large Cell Lymphoma Patients and the General Population. Aesthetic Surgery Journal, 2019, 39, 1065-1070.	0.9	19
50	Adherence to surgical and oncologic standards improves survival in breast cancer patients. Journal of Surgical Oncology, 2019, 120, 148-159.	0.8	12
51	Evolution in practice patterns of axillary management following mastectomy in patients with 1â€"2 positive sentinel nodes. Breast Cancer Research and Treatment, 2019, 176, 435-444.	1.1	20
52	Local Therapy Decisional Regret in Older Women With Breast Cancer: A Population-Based Study. International Journal of Radiation Oncology Biology Physics, 2019, 104, 383-391.	0.4	19
53	Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer. Clinical Cancer Research, 2019, 25, 3996-4013.	3.2	77
54	Surgeon perception versus reality: Opioid use after breast cancer surgery. Journal of Surgical Oncology, 2019, 119, 909-915.	0.8	20

#	Article	IF	Citations
55	Challenges in Clinical Trial Implementation: Results from a Survey of the National Accreditation Program of Breast Centers (NAPBC). Annals of Surgical Oncology, 2019, 26, 4364-4371.	0.7	1
56	Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy. JAMA Oncology, 2019, 5, 45.	3.4	16
57	Feasibility of fineâ€needle aspiration for assessing responses to chemotherapy in metastatic nodes marked with clips in breast cancer: A prospective registry study. Cancer, 2019, 125, 365-373.	2.0	16
58	Ductal Carcinoma In Situ and Margins <2â€Šmm. Annals of Surgery, 2019, 269, 150-157.	2.1	29
59	Comparative Performance of the 7th and 8th Editions of the American Joint Committee on Cancer Staging Systems for Soft Tissue Sarcoma of the Trunk and Extremities. Annals of Surgical Oncology, 2018, 25, 1126-1132.	0.7	30
60	Salvage Surgery for Recurrent Retroperitoneal Well-Differentiated Liposarcoma: Early Reoperation may not Provide Benefit. Annals of Surgical Oncology, 2018, 25, 2193-2200.	0.7	34
61	Breast Implant-Associated Anaplastic Large Cell Lymphoma With Bone Marrow Involvement. Aesthetic Surgery Journal, 2018, 38, .	0.9	5
62	Identification of preoperative factors associated with outcomes following surgical management of intraâ€abdominal recurrent or metastatic GIST following neoadjuvant tyrosine kinase inhibitor therapy. Journal of Surgical Oncology, 2018, 117, 879-885.	0.8	7
63	Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance). American Journal of Roentgenology, 2018, 210, 669-676.	1.0	47
64	Long-term Patient-Reported Outcomes in Older Breast Cancer Survivors: A Population-Based Survey Study. International Journal of Radiation Oncology Biology Physics, 2018, 100, 882-890.	0.4	23
65	Integrating New Knowledge and Surgical Innovation into the Diagnosis and Management of Breast Cancer. Surgical Oncology Clinics of North America, 2018, 27, xv-xvi.	0.6	0
66	Risk factors for locoregional disease recurrence after breastâ€conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient metaâ€analysis. Cancer, 2018, 124, 2923-2930.	2.0	39
67	Factors impacting the accuracy of intra-operative evaluation of sentinel lymph nodes in breast cancer. Breast Journal, 2018, 24, 28-34.	0.4	23
68	A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Annals of Surgery, 2018, 267, 946-951.	2.1	147
69	Expanding Implementation of ACOSOG Z0011 in Surgeon Practice. Clinical Breast Cancer, 2018, 18, 276-281.	1.1	21
70	Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. OncoImmunology, 2018, 7, e1385689.	2.1	46
71	Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. Cancer Research, 2018, 78, 742-757.	0.4	98
72	Concomitant organ resection does not improve outcomes in primary retroperitoneal wellâ€differentiated liposarcoma: A retrospective cohort study at a major sarcoma center. Journal of Surgical Oncology, 2018, 117, 1188-1194.	0.8	31

#	Article	IF	Citations
73	Defining the incidence and clinical significance of lymph node metastasis in soft tissue sarcoma. European Journal of Surgical Oncology, 2018, 44, 170-177.	0.5	82
74	Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell Lymphoma. American Journal of Surgical Pathology, 2018, 42, 293-305.	2.1	80
75	Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer. JAMA Oncology, 2018, 4, 203.	3.4	152
76	Prospective Study of Psychosocial Outcomes of Having Contralateral Prophylactic Mastectomy Among Women With Nonhereditary Breast Cancer. Journal of Clinical Oncology, 2018, 36, 2630-2638.	0.8	38
77	Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. BMC Cancer, 2018, 18, 913.	1.1	69
78	Imaging Surveillance After Definitive Treatment for Breast Cancer. Annals of Surgical Oncology, 2018, 25, 3790-3792.	0.7	1
79	Treatment at lowâ€volume hospitals is associated with reduced shortâ€term and longâ€term outcomes for patients with retroperitoneal sarcoma. Cancer, 2018, 124, 4495-4503.	2.0	100
80	Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies. Cancer Research, 2018, 78, 5481-5491.	0.4	39
81	Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition. Clinical Cancer Research, 2018, 24, 6594-6610.	3.2	70
82	Incorporating Biologic Factors into the American Joint Committee on Cancer Breast Cancer Staging System. Surgical Clinics of North America, 2018, 98, 687-702.	0.5	20
83	Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Reports, 2018, 24, 1434-1444.e7.	2.9	73
84	Satisfaction and Sustainability in a Surgical Career. Annals of Surgical Oncology, 2018, 25, 2785-2789.	0.7	1
85	American Society of Breast Surgeonsâ€™ Practice Patterns After Publication of the SSO-ASTRO-ASCO DCIS Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation. Annals of Surgical Oncology, 2018, 25, 2965-2974.	0.7	16
86	Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. JAMA Surgery, 2017, 152, 665.	2.2	149
87	CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest. Molecular Cancer Therapeutics, 2017, 16, 1751-1764.	1.9	39
88	Recurrence patterns of retroperitoneal leiomyosarcoma and impact of salvage surgery. Journal of Surgical Oncology, 2017, 116, 313-319.	0.8	24
89	Incremental Cancer Detection of Locoregional Restaging with Diagnostic Mammography Combined with Whole-Breast and Regional Nodal Ultrasound in Women with Newly Diagnosed Breast Cancer. Academic Radiology, 2017, 24, 191-199.	1.3	8
90	Quantitative Assessment of Breast Cosmetic Outcome After Whole-Breast Irradiation. International Journal of Radiation Oncology Biology Physics, 2017, 97, 894-902.	0.4	9

#	Article	IF	Citations
91	Society of Surgical Oncology Breast Disease Working Group Statement on Prophylactic (Risk-Reducing) Mastectomy. Annals of Surgical Oncology, 2017, 24, 375-397.	0.7	61
92	Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer. Clinical Cancer Research, 2017, 23, 7288-7300.	3.2	29
93	Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis. JAMA - Journal of the American Medical Association, 2017, 318, 918.	3.8	1,166
94	Bioscore: A Staging System for Breast Cancer Patients that Reflects the Prognostic Significance of Underlying Tumor Biology. Annals of Surgical Oncology, 2017, 24, 3502-3509.	0.7	44
95	Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members. Annals of Surgical Oncology, 2017, 24, 2925-2934.	0.7	54
96	CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nature Communications, 2017, 8, 15916.	5.8	214
97	Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System. Oncologist, 2017, 22, 1292-1300.	1.9	84
98	Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy. Annals of Surgical Oncology, 2017, 24, 652-659.	0.7	41
99	AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. Molecular Cancer Research, 2017, 15, 45-58.	1.5	73
100	Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study. Annals of Surgical Oncology, 2017, 24, 418-424.	0.7	58
101	Cost and Complications of Local Therapies for Early-Stage Breast Cancer. Journal of the National Cancer Institute, 2017, 109, djw178.	3.0	72
102	Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer. Clinical Cancer Research, 2017, 23, 2991-3002.	3.2	46
103	DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. Journal of Cancer, 2017, 8, 2653-2662.	1.2	38
104	Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. Oncotarget, 2017, 8, 14897-14911.	0.8	35
105	Clinical Observations and Molecular Variables of Primary Vascular Leiomyosarcoma. JAMA Surgery, 2016, 151, 347.	2.2	40
106	Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion. Cell Cycle, 2016, 15, 1579-1590.	1.3	31
107	Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells. Cancer Research, 2016, 76, 2406-2418.	0.4	64
108	Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy. International Journal of Radiation Oncology Biology Physics, 2016, 96, 637-644.	0.4	1

#	Article	IF	Citations
109	Limiting Axillary Surgery for Patients with Initial Biopsy-Proven Axillary Metastases After Preoperative Chemotherapy: To Clip or Not to Clip?. Annals of Surgical Oncology, 2016, 23, 3432-3434.	0.7	1
110	Operative and Oncologic Outcomes in 9861 Patients with Operable Breast Cancer: Single-Institution Analysis of Breast Conservation with Oncoplastic Reconstruction. Annals of Surgical Oncology, 2016, 23, 3190-3198.	0.7	119
111	Postmastectomy Radiation Treatment Rates as a Quality Measure: An Opportunity for Compliance Through Collaboration. Annals of Surgical Oncology, 2016, 23, 2377-2379.	0.7	1
112	Cytoplasmic Cyclin E and Phosphoâ€“Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer. American Journal of Pathology, 2016, 186, 1900-1912.	1.9	42
113	A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma: Results from ACOSOG (Alliance) Z1072. Annals of Surgical Oncology, 2016, 23, 2438-2445.	0.7	95
114	Patterns of Local-Regional Management Following Neoadjuvant Chemotherapy in Breast Cancer: Results From ACOSOG Z1071 (Alliance). International Journal of Radiation Oncology Biology Physics, 2016, 94, 493-502.	0.4	33
115	The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy. JAMA Oncology, 2016, 2, 929.	3.4	94
116	Value-Based Breast Cancer Care: A Multidisciplinary Approach for Defining Patient-Centered Outcomes. Annals of Surgical Oncology, 2016, 23, 2385-2390.	0.7	34
117	Use of a Magnetic Tracer for Sentinel Lymph Node Detection in Early-Stage Breast Cancer Patients: A Meta-analysis. Annals of Surgical Oncology, 2016, 23, 1508-1514.	0.7	62
118	Analysis of Clinical and Molecular Factors Impacting Oncologic Outcomes in Undifferentiated Pleomorphic Sarcoma. Annals of Surgical Oncology, 2016, 23, 2220-2228.	0.7	24
119	Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 2016, 15, 593-607.	1.9	54
120	Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. JAMA Oncology, 2016, 2, 508.	3.4	103
121	Complete Surgical Excision Is Essential for the Management of Patients With Breast Implantâ€“Associated Anaplastic Large-Cell Lymphoma. Journal of Clinical Oncology, 2016, 34, 160-168.	0.8	349
122	Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer. Clinical Cancer Research, 2016, 22, 26-33.	3.2	49
123	Organizing a breast cancer database: data management. Chinese Clinical Oncology, 2016, 5, 45-45.	0.4	2
124	Phase 1 adaptive doseâ€finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with highâ€risk extremity and trunk soft tissue sarcoma. Cancer, 2015, 121, 3659-3667.	2.0	17
125	Is Sentinel Lymph Node Dissection Warranted for Patients with a Diagnosis of Ductal Carcinoma In Situ?. Annals of Surgical Oncology, 2015, 22, 4270-4279.	0.7	62
126	Role of Ultrasonography of Regional Nodal Basins in Staging Triple-Negative Breast Cancer and Implications For Local-Regional Treatment. International Journal of Radiation Oncology Biology Physics, 2015, 93, 102-110.	0.4	3

#	Article	IF	Citations
127	Evaluation of the Stage IB Designation of the American Joint Committee on Cancer Staging System in Breast Cancer. Journal of Clinical Oncology, 2015, 33, 1119-1127.	0.8	36
128	<scp>GATA</scp>â€•binding protein 3 enhances the utility of gross cystic disease fluid proteinâ€•15 and mammaglobin A in tripleâ€•negative breast cancer by immunohistochemistry. Histopathology, 2015, 67, 245-254.	1.6	38
129	Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance). Journal of Clinical Oncology, 2015, 33, 3386-3393.	0.8	180
130	Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation. JAMA Oncology, 2015, 1, 931.	3.4	216
131	Selective Surgical Localization of Axillary Lymph Nodes Containing Metastases in Patients With Breast Cancer. JAMA Surgery, 2015, 150, 137.	2.2	148
132	Combined Modality Management of Retroperitoneal Sarcomas: A Single-Institution Series of 121 Patients. International Journal of Radiation Oncology Biology Physics, 2015, 93, 158-165.	0.4	31
133	Simultaneous inference of a misclassified outcome and competing risks failure time data. Journal of Applied Statistics, 2015, 42, 1080-1090.	0.6	2
134	Surgical Considerations After Neoadjuvant Chemotherapy: Breast Conservation Therapy. Journal of the National Cancer Institute Monographs, 2015, 2015, 11-14.	0.9	37
135	Utilization and Outcomes of Breast Brachytherapy in Younger Women. International Journal of Radiation Oncology Biology Physics, 2015, 93, 91-101.	0.4	10
136	Outcomes of Sentinel Lymph Node Dissection Alone vs. Axillary Lymph Node Dissection in Early Stage Invasive Lobular Carcinoma: A Retrospective Study of the Surveillance, Epidemiology and End Results (SEER) Database. PLoS ONE, 2014, 9, e89778.	1.1	37
137	Benefit of Adjuvant Brachytherapy Versus External Beam Radiation for Early Breast Cancer: Impact of Patient Stratification on Breast Preservation. International Journal of Radiation Oncology Biology Physics, 2014, 88, 274-284.	0.4	32
138	The Controversy Regarding Margin Width in Breast Cancer: Enough is Enough. Annals of Surgical Oncology, 2014, 21, 701-703.	0.7	8
139	Mesenchymal to epithelial transition in sarcomas. European Journal of Cancer, 2014, 50, 593-601.	1.3	44
140	Therapeutic radiation dose delivered to the low axilla during whole breast radiation therapy in the prone position: Implications for targeting the undissected axilla. Practical Radiation Oncology, 2014, 4, 116-122.	1.1	7
141	Neoadjuvant Therapy in the Treatment of Breast Cancer. Surgical Oncology Clinics of North America, 2014, 23, 505-523.	0.6	97
142	Locoregional Recurrence Risk for Patients With T1,2 Breast Cancer With 1-3 Positive Lymph Nodes Treated With Mastectomy and Systemic Treatment. International Journal of Radiation Oncology Biology Physics, 2014, 89, 392-398.	0.4	126
143	Crossover Effects of Estrogen Receptor Status on Breast Cancer-Specific Hazard Rates by Age and Race. PLoS ONE, 2014, 9, e110281.	1.1	7
144	Hbo1 Is a Cyclin E/CDK2 Substrate That Enriches Breast Cancer Stem-like Cells. Cancer Research, 2013, 73, 5556-5568.	0.4	46

#	Article	IF	Citations
145	Long term outcomes reporting the safety of breast conserving therapy compared to mastectomy: 20-year results of EORTC 10801. Gland Surgery, 2013, 2, 120-3.	0.5	15
146	LMW-E/CDK2 Deregulates Acinar Morphogenesis, Induces Tumorigenesis, and Associates with the Activated b-Raf-ERK1/2-mTOR Pathway in Breast Cancer Patients. PLoS Genetics, 2012, 8, e1002538.	1.5	35
147	Factors Associated With Local-Regional Recurrence After a Negative Sentinel Node Dissection. Annals of Surgery, 2012, 256, 428-436.	2.1	84
148	Have we made progress in inflammatory breast cancer? Not so fast. Oncology, 2011, 25, 276, 278.	0.4	0
149	Risky Business: Identifying Risk Factors Associated With Lymphedema After Breast Cancer. Archives of Surgery, 2010, 145, 1063.	2.3	0
150	Altered Subcellular Localization of Tumor-Specific Cyclin E Isoforms Affects Cyclin-Dependent Kinase 2 Complex Formation and Proteasomal Regulation. Cancer Research, 2009, 69, 2817-2825.	0.4	39
151	Response to Letter to the Editor: Isolated Tumor Cells in Sentinel Lymph Nodes and Clinical Implications for Early Breast Cancer. Annals of Surgical Oncology, 2009, 16, 2661-2661.	0.7	0
152	Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy is Accurate and Reduces the Need for Axillary Dissection in Breast Cancer Patients. Annals of Surgery, 2009, 250, 558-566.	2.1	270
153	Cyclin E as a prognostic and predictive marker in breast cancer. Seminars in Cancer Biology, 2005, 15, 319-326.	4.3	56
154	GENE THERAPY: Hurdles and Hopes for Cancer Treatment. Science, 2002, 297, 415-416.	6.0	88
155	Sentinel lymph node dissection in early stage breast cancer. Breast Cancer, 2002, 9, 282-288.	1.3	3
156	A Prospective Trial of Preoperative Chemotherapy in Resectable Breast Cancer: Predictors of Breast-Conservation Therapy Feasibility. Annals of Surgical Oncology, 2002, 9, 228-234.	0.7	14
157	Predictors of Locoregional Recurrence Among Patients With Early-Stage Breast Cancer Treated With Breast-Conserving Therapy. Annals of Surgical Oncology, 2002, 9, 256-265.	0.7	5
158	Long-Term Complications Associated With Breast-Conservation Surgery and Radiotherapy. Annals of Surgical Oncology, 2002, 9, 543-549.	0.7	12
159	Unusual Aspects of Breast Cancer. Journal of Clinical Oncology, 2001, 19, 2573-2574.	0.8	17
160	Educational Review: Role of the Surgeon in Hereditary Breast Cancer. Annals of Surgical Oncology, 2001, 8, 368-378.	0.7	5
161	Feasibility of Breast Preservation in the Treatment of Occult Primary Carcinoma Presenting With Axillary Metastases. Annals of Surgical Oncology, 2001, 8, 425-431.	0.7	117
162	Utility of Breast Sentinel Lymph Node Biopsy Using Day-Before-Surgery Injection of High-Dose 99mTc-Labeled Sulfur Colloid. Annals of Surgical Oncology, 2001, 8, 821-827.	0.7	43

#	Article	IF	Citations
163	Breast conservation therapy as a treatment option for the elderly. Cancer, 2001, 92, 1092-1100.	2.0	50
164	Feasibility of Breast Preservation in the Treatment of Occult Primary Carcinoma Presenting With Axillary Metastases. , 2001, 8, 425.		1
165	The feasibility of minimally invasive surgery for Stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy. , 2000, 88, 1417-1424.		51
166	Primary treatment of cystosarcoma phyllodes of the breast. Cancer, 2000, 89, 1502-1511.	2.0	320
167	Prognostic Implications of Pathological Lymph Node Status After Preoperative Chemotherapy for Operable T3N0M0 Breast Cancer. Annals of Surgical Oncology, 2000, 7, 435-440.	0.7	26
168	Ductal Carcinoma-In-Situ: Long-Term Results of Breast-Conserving Therapy. Annals of Surgical Oncology, 2000, 7, 656-664.	0.7	38
169	Primary treatment of cystosarcoma phyllodes of the breast. , 2000, 89, 1502.		2
170	Tumor Suppressor Gene Smad4/DPC4, Its Downstream Target Genes, and Regulation of Cell Cyclea. Annals of the New York Academy of Sciences, 1999, 880, 31-37.	1.8	27
171	Feasibility of Breast Conservation Therapy in Metachronous or Synchronous Bilateral Breast Cancer. Annals of Surgical Oncology, 1999, 6, 102-108.	0.7	31
172	Local Recurrence and Survival Among Black Women With Early-Stage Breast Cancer Treated With Breast-Conservation Therapy or Mastectomy. Annals of Surgical Oncology, 1999, 6, 241-248.	0.7	32
173	Primary Tumor Response to Induction Chemotherapy as a Predictor of Histological Status of Axillary Nodes in Operable Breast Cancer Patients. Annals of Surgical Oncology, 1999, 6, 762-767.	0.7	31
174	Preclinical experimental therapeutic approaches in soft tissue sarcoma. , 1999, 17, 78-82.		6
175	Special considerations in breast cancer risk and survival. , 1999, 71, 250-260.		5
176	Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer. Annals of Surgical Oncology, 1998, 5, 673-680.	0.7	72
177	Synchronous elective contralateral mastectomy and immediate bilateral breast reconstruction in women with early-stage breast cancer. Annals of Surgical Oncology, 1998, 5, 529-538.	0.7	32
178	Presentation, treatment, and outcome of local recurrence after skin-sparing mastectomy and immediate breast reconstruction. Annals of Surgical Oncology, 1998, 5, 620-626.	0.7	221
179	Role of conservation therapy for invasive lobular carcinoma of the breast. Annals of Surgical Oncology, 1997, 4, 650-654.	0.7	42
180	Feasibility of postmastectomy radiation therapy after TRAM flap breast reconstruction. Annals of Surgical Oncology, 1997, 4, 377-384.	0.7	104

#	Article	IF	Citations
181	Clinical Manifestations and Surgical Management of Breast Implant-Associated Anaplastic Large Cell Lymphoma: Beyond the NCCN Guidelines. Annals of Surgical Oncology, 0, , .	0.7	4